Inclusion Criteria:

          1. Males and females ≥ 18 years old

          2. Participants must have histological diagnosis of local advanced (primary or recurrent)
             or metastatic solid tumors that are not amenable for treatment with curative intent

          3. Participants must be in need of systemic treatment for their cancer and either are
             refractory to or have failed treatment with, are intolerant to or have refused, or are
             not otherwise a candidate, in the opinion of the Investigator, for any of the
             currently available established therapies

          4. Participants must have available a fresh or recent tumor tissue sample from a
             diagnostic biopsy/surgery or a metastatic tumor biopsy;

          5. Participants must have measurable disease by response evaluation criteria in solid
             tumors (RECIST) v1.1; or participants may have bone metastatic disease evaluable by
             Prostate Cancer Working Group 2 (PCWG2) for participants with metastatic
             castration-resistant prostate cancer (mCRPC), or according to the tumor evaluation
             criteria best suited and accepted for the tumor type being evaluated

          6. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status
             (PS) 0 or 1

          7. Participants must be willing and able to comply with the scheduled visits, treatment
             plan, laboratory tests and other specified study procedures

        Exclusion Criteria:

          1. Known history or positive test for human immunodeficiency virus (HIV), hepatitis C
             virus (HCV) or chronic hepatitis B virus (HBV) infection.

          2. Active infection requiring intravenous (IV) antibiotics

          3. History of cerebrovascular accident (CVA), myocardial infarction or unstable angina
             within the previous 6 months before starting therapy.

          4. Participants with uncontrolled Type I or II diabetes mellitus (DM); uncontrolled DM

          5. Participants with prior anti-cancer therapy within 2 weeks prior to study enrollment
             or prior radiation therapy within 2 weeks prior to study enrollment.